Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
dostarlimab moa | 1.18 | 1 | 3868 | 25 | 15 |
dostarlimab | 1.19 | 0.3 | 5248 | 74 | 11 |
moa | 0.68 | 0.6 | 2868 | 31 | 3 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
dostarlimab moa | 1.65 | 1 | 5583 | 13 |
dostarlimab manufacturer | 0.02 | 0.5 | 8574 | 53 |
dostarlimab macmillan | 0.03 | 0.7 | 9799 | 23 |
dostarlimab mode of action | 0.98 | 0.2 | 5954 | 87 |
dostarlimab molecule | 1.31 | 0.3 | 7727 | 39 |
dostarlimab maker | 0.59 | 0.6 | 1767 | 28 |
dostarlimab monograph | 1.79 | 0.1 | 5621 | 85 |
dostarlimab mayo clinic | 1.54 | 0.1 | 152 | 1 |
dostarlimab manufacturer stock | 1.13 | 0.4 | 8416 | 3 |
dostarlimab endometrial cancer | 1.22 | 0.5 | 7100 | 52 |
dostarlimab ema | 1.41 | 0.5 | 1877 | 26 |
dostarlimab emc | 0.4 | 0.4 | 7873 | 50 |
dostarlimab epar | 1.04 | 0.3 | 4548 | 12 |
dostarlimab endometrio | 1.97 | 0.3 | 5921 | 54 |
dostarlimab ema approval | 1.48 | 1 | 7785 | 54 |
dostarlimab effets secondaires | 0.31 | 0.8 | 4319 | 67 |
dostarlimab effetti collaterali | 0.9 | 0.5 | 1171 | 48 |
dostarlimab endometrial cancer approval | 0.41 | 0.6 | 9030 | 66 |
dostarlimab endometrial cancer fda | 1.77 | 0.4 | 9044 | 27 |